department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Bosutinib · pharmadog

pharmadog
drugs
Bosutinib

drug

patient view →

bosutinib

Marketedupdated 2mo ago

by Alembic Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Bosutinib

generic

bosutinib

indication

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 26, 2026

81 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (40)

Aug 28, 2034patentUS 11103497*PED
Aug 28, 2034patentUS 11103497*PED
Aug 28, 2034patentUS 11103497*PED
Aug 28, 2034patentUS 11103497*PED
Aug 28, 2034patentUS 11103497*PED
Feb 28, 2034method-of-use (U-3217)US 11103497
Feb 28, 2034method-of-use (U-3217)US 11103497
Feb 28, 2034method-of-use (U-3217)US 11103497
Feb 28, 2034method-of-use (U-3217)US 11103497
Feb 28, 2034method-of-use (U-3217)US 11103497
May 23, 2027patentUS 7767678*PED320d
May 23, 2027patentUS 7767678*PED320d
May 23, 2027patentUS 7767678*PED320d
May 23, 2027patentUS 7767678*PED320d
May 23, 2027patentUS 7767678*PED320d
Nov 23, 2026compositionUS 7767678139d
Nov 23, 2026compositionUS 7767678139d
Nov 23, 2026compositionUS 7767678139d
Nov 23, 2026compositionUS 7767678139d
Nov 23, 2026compositionUS 7767678139d
Jun 11, 2026patentUS 7417148*PED
Jun 11, 2026patentUS 7417148*PED
Jun 11, 2026patentUS 7417148*PED
Jun 11, 2026patentUS 7417148*PED
Jun 11, 2026patentUS 7417148*PED
Jun 11, 2026patentUS 7919625*PED
Jun 11, 2026patentUS 7919625*PED
Jun 11, 2026patentUS 7919625*PED
Jun 11, 2026patentUS 7919625*PED
Jun 11, 2026patentUS 7919625*PED
Dec 11, 2025method-of-use (U-3708)US 7417148
Dec 11, 2025method-of-use (U-3708)US 7417148
Dec 11, 2025method-of-use (U-3707)US 7417148
Dec 11, 2025method-of-use (U-3707)US 7417148
Dec 11, 2025method-of-use (U-3708)US 7417148
Dec 11, 2025formulationUS 7919625
Dec 11, 2025formulationUS 7919625
Dec 11, 2025formulationUS 7919625
Dec 11, 2025formulationUS 7919625
Dec 11, 2025formulationUS 7919625

FDA exclusivities (20)

Mar 26, 2031PEDPediatric (6mo bonus)4.7y
Mar 26, 2031PEDPediatric (6mo bonus)4.7y
Mar 26, 2031PEDPediatric (6mo bonus)4.7y
Mar 26, 2031PEDPediatric (6mo bonus)4.7y
Mar 26, 2031PEDPediatric (6mo bonus)4.7y
Sep 26, 2030ODE-444Orphan Drug (7y)4.2y

🐶 often sniffed alongside

top 4

tagApproval48 co-mentions · 24 sources
drugBosulif47 co-mentions · 24 sources
drugBOSUTINIB MONOHYDRATE24 co-mentions · 24 sources
tagSmall Molecule24 co-mentions · 24 sources

Sep 26, 2030ODE-444Orphan Drug (7y)4.2y

Sep 26, 2030ODE-444Orphan Drug (7y)4.2y

Sep 26, 2030ODE-444Orphan Drug (7y)4.2y

Sep 26, 2030ODE-444Orphan Drug (7y)4.2y

Mar 26, 2027PEDPediatric (6mo bonus)262d

Mar 26, 2027PEDPediatric (6mo bonus)262d

Mar 26, 2027PEDPediatric (6mo bonus)262d

Mar 26, 2027PEDPediatric (6mo bonus)262d

Mar 26, 2027PEDPediatric (6mo bonus)262d

Sep 26, 2026I-923Indication (3y)81d

Sep 26, 2026NPNP81d

Sep 26, 2026I-923Indication (3y)81d

Sep 26, 2026I-923Indication (3y)81d

Sep 26, 2026NPNP81d

Trials studying bosutinib

phase4Asciminib Roll-over Studyrecruitingn=347
phase3A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPactive not recruitingn=405
phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)recruitingn=720
phase2Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemiaactive not recruitingn=60
phase3Study of Olverembatinib (HQP1351) in Patients With CP-CMLrecruitingn=285
phase3Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIscompletedn=233
phase1WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitorcompletedn=19
phase1Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Conditioncompletedn=18

more trials →